The Histiocyte Society is offering an annual prize for the best poster presented at the Annual Meeting. It will be given in honor of Dr. Robert J. Arceci, world renowned pediatric oncologist, scientist and teacher with invaluable contributions to the field of histiocytoses. 

Dr. Arceci completed his undergraduate studies at Trinity College, received his Ph.D. and M.D. from the University of Rochester, and then completed his Residency in Pediatrics and Fellowship in Pediatric Hematology/Oncology at Boston Children’s Hospital and Harvard Medical School. Following faculty appointments at Harvard Medical School, Dana-Farber Cancer Institute and Boston Children’s Hospital, he became Director of Pediatric Hematology/Oncology at Cincinnati Children’s Hospital Medical Center.  In 2000, Dr. Arceci became Director and King Fahd Professor of Pediatric Oncology and Professor of Oncology and Pediatrics at the Johns Hopkins University School of Medicine where he work until 2012.  

In late 2012, Dr. Arceci joined Phoenix Children’s Hospital as Co-Director of the Ronald A. Matricaria Institute of Molecular Medicine and held the dual role of Division Chief for the Center for Cancer and Blood Disorders at Phoenix Children’s Hospital. He also served as a professor of Pediatrics on the faculty at the University of Arizona College of Medicine-Phoenix, Department of Child Health.

Dr. Arceci was a member of numerous scientific and medical societies, advisory committees and review boards, and has been the recipient of several prestigious honors and awards. He has served on a variety of committees in the Pediatric Oncology Group, the Children’s Cancer Group and the Children’s Oncology Group, including Chairperson for the Myeloid Leukemia Committee and Vice-Chair of the Biology and Therapeutics Translational Committee.  Dr. Arceci was Editor-in-Chief of Pediatric Blood and Cancer and previously served as Editor-in-Chief of the Journal of Pediatric Hematology/Oncology and Associate editor of the Journal of Pediatrics. In addition to these leadership roles, Dr. Arceci was an excellent clinician, known both nationally and internationally. He was considered one of the world’s experts on histiocytic disorders and pediatric acute myelocytic leukemia (AML). 

Dr. Arceci was an active member of the Histiocyte Society for many years and a beloved colleague, friend and mentor. In addition, he played an integral role as the Chairman of the Nikolas Symposium to promote translational research in Langerhans cell histiocytosis. 

The prize will be awarded to (1) poster presenter whose poster demonstrates an exceptional level of science and relevance to the histiocytic disorders and is presented in a clear, original and organized manner.

The abstracts selected for poster presentations which receive one of the top ten scores will be recognized as finalists for consideration for this award. Final selection of the award winner will be made through a separate round of grading to occur during the Poster Presentation Session at the Annual Meeting. Only those poster presenters in attendance of this session will be considered eligible for the award.

It is understood that the winning poster may have co-authors, but that the first author must be the leader of the project and the one who is awarded the Robert J. Arceci Award for Best Poster. The decision by a special committee of the Histiocyte Society will be based on scientific content, originality, relevance and organization of presentation. The prize will consist of $250 US Dollars and a certificate. This award will be presented during the Closing Ceremonies of the Annual Meeting.

PREVIOUS RECIPIENTS

2023 Recipient
Susana Garcia-Obregon, Biobizkaia Health Research Institute, Barakaldo, Spain
for the abstract entitled:
SEARCHING FOR DIFFERENTIAL DIAGNOSTIC BIOMARKERS BETWEEN SEVERE SEPSIS AND HEMOPHAGOCYTIC SYNDROME FOR A BETTER CLINICAL MANAGEMENT IN PEDIATRIC PATIENTS

2022 Recipient
Kerstin Schütze, University Medical Center Eppendorf, Hamburg, Germany (Presented by Kai Lehmberg)
for the abstract entitled:
MAP KINASE ACTIVATING DEATH DOMAIN (MADD) DEFICIENCY IS A NOVEL CAUSE OF IMPAIRED LYMPHOCYTE CYTOTOXICITY

2019 Recipient
Hirofumi Shibata, Kyoto University
for the abstract entitled:
THE FEASIBILITY OF NEWBORN MASS SCREENING FOR PRIMARY HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS USING DRIED BLOOD SPOT (DBS) PROTEOMICS

2018 Recipient
Amel Sengal, Texas Children's Cancer Center
for the abstract entitled:
DIFFERENTIAL EXPRESSION OF MICRORNAS IN PLASMA OF LANGERHANS CELL HISTIOCYTOSIS (LSH) PATIENTS AND CORRELATION WITH T CELL EXHAUSTION